Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Screening Technique Finds Endothelial Cells Targeted by Nanoparticles

By LabMedica International staff writers
Posted on 18 Oct 2018
A recently developed technique allows researchers to identify lipid nanoparticles that preferentially target endothelial cells – rather than liver cells – for transport of the components of the CRISPR/Cas9 gene-editing tool.

Nanoparticle-mediated delivery of siRNA to hepatocytes has been used to treat disease in humans. More...
However, systemically delivering RNA drugs to tissues other than the liver has remained an important challenge, primarily because there is no high-throughput method to identify nanoparticles that deliver functional mRNA to cells in vivo.

To increase the number of nanoparticles that could be studied in vivo, investigators at the Georgia Institute of Technology (Atlanta, USA) designed a high-throughput method for which they coined the name FIND (Fast Identification of Nanoparticle Delivery). This method is capable of quantifying how more than 100 lipid nanoparticles (LNPs) deliver mRNA that is translated into functional protein.

To prepare the nanoparticles nucleic acids (mRNA, DNA barcodes, siRNA, and sgRNA) were diluted in citrate buffer while lipid-amine compounds, alkyl-tailed PEG, cholesterol, and helper lipids were diluted in ethanol. The nanoparticles were generated by combining the citrate and ethanol phases by syringes in a microfluidic device.

The FIND technique also introduced a red-colored tracer protein (Cre) into cells. This was done by co-delivering Cas9 mRNA and single-guide RNA, which induced endothelial cell gene editing.

The investigators reported in the October 1, 2018, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America that they had measured how more than 250 LNPs were able to deliver mRNA to multiple cell types in vivo and identified two LNPs that efficiently delivered siRNA, single-guide RNA (sgRNA), and mRNA to endothelial cells. One of the nanoparticles delivered Cas9 mRNA and sgRNA to splenic endothelial cells as efficiently as hepatocytes, distinguishing it from LNPs that delivered Cas9 mRNA and sgRNA to hepatocytes more than other cell types.

"We hope to take projects that would ordinarily require years and complete several of them within the next 12 months," said senior author Dr. James E. Dahlman, assistant professor of biomedical engineering at the Georgia Institute of Technology. "FIND could be used to carry all sorts of nucleic acid drugs into cells. That could include small RNAs, large RNAs, small DNAs and large DNAs - many different types of genetic drugs that are now being developed in research labs."

Related Links:
Georgia Institute of Technology


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.